Glucotrack, Inc. announced the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent diabetes. The primary goal of the feasibility study was to demonstrate that the CGM sensor design could reliably report glucose measurements for two years post-implant. Laboratory bench testing confirmed that a minimum two-year implant longevity is highly probable with the current sensor design.

The implant longevity was independently verified by a third-party using sensor parameters to simulate sensor performance over time. Given the positive results of the study, the Company is now preparing for long-term animal studies, which are expected to begin later this year. Glucotrack is committed to commercializing an implantable CGM with long-term sensor life with no requirement for any additional wearable component, and a once-only calibration.

The Company believes that these will be key differentiators as compared to other continuous glucose monitors, either currently on the market or known to be in development.